Epigenetics and Psychiatry

Neurotherapeutics

Volumn 10, Issue 4, 2013, Pages 734-741

  Mahgoub, Melissa ^a   Monteggia, Lisa M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Addiction; Depression; Epigenetics; Histone; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID; CLOZAPINE; COCAINE; ENTINOSTAT; FLUOXETINE; GLUTAMATE DECARBOXYLASE 67; HISTONE DEACETYLASE 5; IMIPRAMINE; MESSENGER RNA; PROTEIN C FOS; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ADDICTION; ANHEDONIA; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; COCAINE DEPENDENCE; CORPUS STRIATUM; DEPRESSION; DNA METHYLATION; EMOTIONAL DISORDER; EPIGENETICS; HALLUCINATION; HISTONE METHYLATION; HUMAN; LOSS OF APPETITE; MAJOR DEPRESSION; MOLECULAR MECHANICS; NONHUMAN; PARANOIA; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER;

DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION; HISTONES; HUMANS; MENTAL DISORDERS; PSYCHIATRY;

EID: 84886303172     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0213-6     Document Type: Review

References (73)

1. Kendler KS. Twin studies of psychiatric illness: an update. Arch Gen Psychiatry 2001;58: 1005-14.
2. Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci USA 2001;98: 12320-2.
3. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34: 13-25.
4. McEwen BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000;48: 721-31.
5. Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science 1975;187: 226-32.
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33 Suppl: 245-54.
7. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007;128: 635-8.
8. Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003;421: 448-53.
9. Borrelli E, Nestler EJ, Allis CD, Sassone-Corsi P. Decoding the epigenetic language of neuronal plasticity. Neuron 2008;60: 961-74.
10. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321: 209-13.
11. Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and chromatin. Cell 1999;99: 451-4.
12. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74: 481-514.
13. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62: 617-27.
14. Fava M, Kendler KS. Major depressive disorder. Neuron 2000;28: 335-41.
15. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358: 55-68.
16. Castren E, Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010;70: 289-97.
17. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54: 597-606.
18. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50: 260-5.
19. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997;56: 131-7.
20. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22: 3251-61.
21. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004;101: 10827-32.
22. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 2007;61: 187-97.
23. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008;63: 642-9.
24. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59: 1116-27.
25. Sapolsky RM. Stress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress 1996;1: 1-19.
26. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995;15: 1768-77.
27. Nibuya M, Takahashi M, Russell DS, Duman RS. Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 1999;267: 81-4.
28. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004;55: 708-14.
29. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9: 519-25.
30. Onishchenko N, Karpova N, Sabri F, Castren E, Ceccatelli S. Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. J Neurochem 2008;106: 1378-87.
31. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006;311: 864-8.
32. Golden SA, Christoffel DJ, Heshmati M, Hodes GE, Magida J, Davis K et al. Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med 2013;19: 337-44.
33. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 2012;18: 1413-7.
34. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 2013;110: 4804-9.
35. Chiechio S, Copani A, Zammataro M, Battaglia G, Gereau RWt, Nicoletti F. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010;31: 153-60.
36. Overstreet DH, Friedman E, Mathe AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005;29: 739-59.
37. Matrisciano F, Caruso A, Orlando R, Marchiafava M, Bruno V, Battaglia G et al. Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 2008;55: 525-31.
38. Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt JD et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci 2010;13: 423-30.
39. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory formation. Neuron 2007;53: 857-69.
40. Levenson JM, Roth TL, Lubin FD, Miller CA, Huang IC, Desai P et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 2006;281: 15763-73.
41. LaPlant Q, Vialou V, Covington HE, 3rd, Dumitriu D, Feng J, Warren BL et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat Neurosci 2010;13: 1137-43.
42. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004;47 Suppl 1: 24-32.
43. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2: 119-28.
44. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 2007;10: 1029-37.
45. Lu L, Dempsey J, Liu SY, Bossert JM, Shaham Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J Neurosci 2004;24: 1604-11.
46. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003;23: 742-7.
47. Im HI, Hollander JA, Bali P, Kenny PJ. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat Neurosci 2010;13: 1120-7.
48. Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005;48: 303-14.
49. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011;12: 623-37.
50. Levine AA, Guan Z, Barco A, Xu S, Kandel ER, Schwartz JH. CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc Natl Acad Sci USA 2005;102: 19186-91.
51. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10: 32-42.
52. Renthal W, Maze I, Krishnan V, Covington HE, 3rd, Xiao G, Kumar A et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007;56: 517-29.
53. Romieu P, Host L, Gobaille S, Sandner G, Aunis D, Zwiller J. Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats. J Neurosci 2008;28: 9342-8.
54. Sun J, Wang L, Jiang B, Hui B, Lv Z, Ma L. The effects of sodium butyrate, an inhibitor of histone deacetylase, on the cocaine- and sucrose-maintained self-administration in rats. Neurosci Lett 2008;441: 72-6.
55. Wang L, Lv Z, Hu Z, Sheng J, Hui B, Sun J et al. Chronic cocaine-induced H3 acetylation and transcriptional activation of CaMKIIalpha in the nucleus accumbens is critical for motivation for drug reinforcement. Neuropsychopharmacology 2010;35: 913-28.
56. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23: 9418-27.
57. Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E et al. Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. Nat Neurosci 2013;16: 434-40.
58. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50: 85-94.
59. Carpenter WT, Jr., Buchanan RW. Schizophrenia. N Engl J Med 1994;330: 681-90.
60. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10: 27-39.
61. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004;9: 14-27.
62. Costa E, Chen Y, Davis J, Dong E, Noh JS, Tremolizzo L et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interv 2002;2: 47-57.
63. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One 2007;2: e809.
64. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57: 1061-9.
65. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 2002;30: 2930-9.
66. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005;134B: 60-6.
67. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005;102: 9341-6.
68. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 2002;99: 17095-100.
69. Chen Y, Dong E, Grayson DR. Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. Neuropharmacology 2011;60: 1075-87.
70. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 2005;102: 2152-7.
71. Zhubi A, Veldic M, Puri NV, Kadriu B, Caruncho H, Loza I et al. An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 2009;111: 115-22.
72. Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA 2007;104: 4676-81.
73. Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012;15: 1245-54.